What’s in Store at the 2025 Psychiatry Update? Sneak Preview!
Drs. Christoph Correll, Leslie Citrome, & Donald Black Give a Sneak Preview…
Welcome back to the Psychiatry newsletter! Quite a bit has been going on over the past year in psychiatry research and development. We strive in this newsletter to help keep you updated on these advances as they progress from research to practice. Please let us know if there are topics you’d like to see get more coverage.
In this issue, catch up with some of Medscape’s faculty Drs. Christoph Correll, Leslie Citrome, and Donald Black, who give a preview of topics from the 2025 Psychiatry Update that comprise new critical treatment options and therapies they have adopted into practice and look forward to on the horizon. Read on to see what they say about what they’re finding success with for their patients!
Need CME? We’ve got you covered—Don’t Miss!
March 20-22, 2025; Marriott Marquis Downtown Magnificent Mile, Chicago, Illinois
- Full 3-day meeting with interactive presentations, discussion and networking opportunities in addition to the scientific sessions.
- Stellar agenda! Explore the latest advances in the treatment and management of bipolar disorder, MDD, schizophrenia, PTSD, ADHD, neuropsychiatric disorders, movement disorders, as well as innovative practice approaches such as neuromodulation and digital technologies.
- Hear from internationally renowned faculty who present the most up-to-date, clinically relevant information and research.
- Take home the kind of breakthroughs that can make a difference in your patients’ lives!
- Register by clicking here!
Can’t make it to the Psychiatry Update conference? Check out:
Psychopharmacology Update 2025 | October 17-18, 2025 | Cincinnati, OH
Psychopharmacology Update is back in Cincinnati, Ohio! Join your colleagues and learn from the experts on the latest breakthroughs in psychiatry. You won’t want to miss it! Register here to save your spot and lock in the best available rate!
Thank you to Dr. Christoph Correll, Dr. Leslie Citrome, and Dr. Donald Black for this month’s interview! Please contact me at colleen@cmhadvisors.com with any comments. –Colleen Hutchinson
What’s in Store at the 2025 Psychiatry Update? Sneak Preview!
With Drs. Christoph Correll, Leslie Citrome, & Donald Black
As Chair, what do you aim for attendees to leave with from the upcoming Psychiatry Update?
Dr. Citrome: To pick up some tips from our expert presenters on what to look for to make a diagnosis and what new interventions are worth considering.
What do you anticipate attendees coming away with from the upcoming Psychiatry Update?
Dr. Correll: The most up to date clinically useful information regarding the assessment, diagnosis and comprehensive treatment of people living with mental illness.
Dr. Correll and Dr. Citrome, you both will co-present Psychiatric Treatment Innovations: New Therapeutics, Novel Mechanisms of Action, and Pipeline Developments. What are some of the latest new therapeutics that have been of great import to treatment options and algorithms for patients?
Dr. Correll: Lumateperone across unipolar and bipolar depressive disorders; xanomeline-trospium for the treatment of schizophrenia; olanzapine-samidorphan to reduce olanzapine's cardiometabilic burden; one-monthly and two-monthly immediate release subcutaneous long-acting risperidone for relapse prevention.
Dr. Citrome: For the treatment of schizophrenia, we need to get up to speed on muscarinic receptor agonism, and for major depressive disorder, we need a better understanding of agents that work on glutamatergic receptors.
Dr. Black, you serve as Advisory Chair and have been involved on a leadership level with Medscape Psychiatry Update for some time. Serving in this capacity, how do you determine what topics and breakthroughs are current and appropriate for the Psych Update agenda, plus who should cover them?
Dr. Black: The process is collaborative. It starts by having an understanding of the literature, attending Medscape meetings, and talking with attendees about their interests and concerns. What do they want to learn at meetings? What topics are of interest to them, and which are most relevant to their practice? At Medscape meetings, I carefully listen to presenters. I carefully assess speaking style (are they strong presenters?), accuracy and utility of their information (can clinicians use this?), and the PowerPoint itself (Is it attractive? Easy to follow? Well organized?). Does the speaker stay on topic and watch the clock? Then along with other experienced clinicians and staff, we meet to consider the topics for the next meeting (we aim for a broad swath), potential speakers, and even how to group presentations for maximum impact. We include lengthy Q&A sessions because they often tend to be the most popular and informative part of the meeting. That’s it. And the staff bring it all together.
Dr. Citrome, on Saturday, you present The Role of Psychiatric Care in Treating Eating Disorders. How has this role grown and changed over time as more is learned about these disorders?
Dr. Citrome: Now that binge eating disorder is included in the DSM, it is more straightforward to describe it to patients who may have this disorder but who did not know it is a treatable illness (and not just a "bad habit").
Dr. Correll, with Drs. Breier and Meyer, you present Revolutionizing Schizophrenia Treatment: Integrating Muscarinic Receptor Agents Into Clinical Practice. How have muscarinic receptor agents been revolutionary in treating schizophrenia?
Dr. Correll: Treatment of psychosis via reduction of presynaptic dopamine release through interaction with cholinergic, GABAergic, glutamatergic and dopamine transmission, without association with neuromotor, prolactin-related, arousal-related and cardiometabolic adverse effects.
Dr. Black, can you give us a couple pearls (or a short overview/bullet points) you’ll be covering in your upcoming Medscape Psychiatry Update presentation, Pharmocotherapy for Management of Co-occurring Personality Disorders in Psychiatric Conditions?
Dr. Black:
- Psychotherapy is the treatment of choice for personality disorders (PD) but many patients can also benefit from pharmacotherapy.
- Three strategies for choosing medication have been described: 1) target the syndrome; 2) target major symptom dimensions (eg, aggression/anger); and 3) target the comorbid disorders (eg, depression, panic disorder, substance abuse).
- Treating comorbid disorders can have the benefit of reducing the overall severity of the PD.
Psychiatry Resource Section
Medscape Medical News Article: Polypharmacy in Psychiatry: Good, Bad, or Just Unavoidable?
Loading ...